Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Celgene (Nasdaq: CELG ) has earned a respected four-star ranking.
With that in mind, let's take a closer look at Celgene's business and see what CAPS investors are saying about the stock right now.
|Headquarters (founded)||Summit, N.J. (1980)|
|Market Cap||$31.4 billion|
|Trailing-12-Month Revenue||$5.0 billion|
|Management||Chairman/CEO Robert Hugin
CFO Jacqualyn Fouse
|Return on Equity (average, past 3 years)||20.4%|
|Cash/Debt||$2.3 billion / $1.4 billion|
Johnson & Johnson
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 96% of the 1,535 members who have rated Celgene believe the stock will outperform the S&P 500 going forward.
My favorite biotech stock. Although there may be better [speculative] plays out there, [Celgene] is already established with high earnings growth and a compelling valuation. This company has many drugs in the pipeline to continue its growth for the future.
If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite a strong four-star rating, Celgene may not be your top choice.
We've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2012." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.